Phenformin as prophylaxis and therapy in breast cancer xenografts.

British Journal of Cancer
M V C L AppleyardA M Thompson

Abstract

Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the efficacy of the biguanide phenformin in the chemoprophylaxis and in the treatment of oestrogen receptor (ER)-positive MCF7 and receptor triple-negative MDAMB231 xenografts in immunocompromised mice. We also compared the efficacy of phenformin and metformin in the treatment of MDAMB231. Immunocompromised mice were divided into groups: (1) phenformin administered for 2 weeks prior to cell injection; (2) established tumours treated with phenformin; (3) established tumours treated with metformin (only for MDAMB231 tumours); (4) untreated controls. Post-treatment tumours, liver and spleen were harvested for further analysis. Phenformin significantly inhibited both the development and growth of MCF7 and MDAMB231 tumours, and for MDAMB231 at greater efficacy than metformin without murine toxicity. The number of mitotic figures was significantly fewer in xenografts treated with phenformin compared with controls. Results suggested that the mechanism of action of phenformin in vivo is consistent with AMPK activation. Phenformin has clinical pote...Continue Reading

References

Aug 15, 1968·Experientia·G Lugaro, G Giannattasio
Oct 1, 1993·The Annals of Pharmacotherapy·M E McGuinness, R L Talbert
Feb 29, 1996·The New England Journal of Medicine·C J Bailey, R C Turner
Nov 14, 1997·Nature Medicine·M SkobeN E Fusenig
Oct 17, 2001·The Journal of Clinical Investigation·G ZhouD E Moller
Jul 3, 2002·Annals of Internal Medicine·Dmitri KirpichnikovJames R Sowers
Aug 27, 2002·Annual Review of Pharmacology and Toxicology·Edward A SausvilleGeorge Kim
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marie-France Demierre, Larry Nathanson
Nov 19, 2003·Life Sciences·Filippo CaraciAlfredo Bianchi
Jan 22, 2005·Current Opinion in Genetics & Development·Neil A Bhowmick, Harold L Moses
Feb 4, 2005·The New England Journal of Medicine·Jeffrey A Meyerhardt, Robert J Mayer
Apr 26, 2005·BMJ : British Medical Journal·Josie M M EvansAndrew D Morris
May 4, 2005·Molecular Cell·Russell G JonesCraig B Thompson
Jul 30, 2005·International Journal of Cancer. Journal International Du Cancer·Alexandre ChlenskiSusan L Cohn
Aug 30, 2005·Experimental Gerontology·Vladimir N AnisimovClaudio Franceschi
Mar 21, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Li ZhangJames A Balschi
Mar 18, 2008·Critical Reviews in Oncology/hematology·Sirwan M HadadAlastair M Thompson
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pamela J GoodwinVuk Stambolic
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sao JiralerspongAna M Gonzalez-Angulo
Nov 18, 2009·Diabetes Care·Gijs W D LandmanHenk J G Bilo
Dec 17, 2009·The Oncologist·Curtis R Chong, Bruce A Chabner
Mar 23, 2011·Molecular Cancer Research : MCR·Yongxian Zhuang, W Keith Miskimins

❮ Previous
Next ❯

Citations

Jan 8, 2014·Nature Reviews. Endocrinology·Ida Pernicova, Márta Korbonits
Mar 1, 2014·British Journal of Cancer·Y LiuP J Coates
Jul 9, 2014·Proceedings of the National Academy of Sciences of the United States of America·Andreas JanzerKevin Struhl
Jul 2, 2015·International Neurourology Journal·Wun-Jae Kim
May 1, 2012·Cell Cycle·Alastair M Thompson, Timothy J Newman
Dec 18, 2014·Nature Chemical Biology·Samuel E Weinberg, Navdeep S Chandel
Jun 10, 2016·Cell Death & Disease·E Panieri, M M Santoro
Dec 31, 2016·Metabolic Engineering·Seth J ParkerChristian M Metallo
May 8, 2018·Genes·Giulia LeoneLuisa Iommarini
Sep 10, 2014·International Journal of Cancer. Journal International Du Cancer·Stefania OrecchioniFrancesco Bertolini
Oct 12, 2013·Nature Reviews. Drug Discovery·Lorenzo GalluzziGuido Kroemer
Jun 25, 2013·Molecules and Cells·Yeon Kyung Choi, Keun-Gyu Park
Dec 29, 2012·Current Diabetes Reports·Etan Orgel, Steven D Mittelman
Sep 4, 2013·The Journal of Clinical Investigation·Michael Pollak
Jan 28, 2014·PloS One·W Keith MiskiminsJoon Young Choi
Oct 4, 2019·Antioxidants & Redox Signaling·Hsin Yao ChiuReshma Taneja
Jan 10, 2020·Drug Development Research·Raghunandan YendapallyBrittany La-Viola
Mar 31, 2017·Oncology Letters·Daniela Fortunato RêgoEliete Neves Silva Guerra
Jun 25, 2015·Carcinogenesis·Stephanie C CaseyDean W Felsher
Aug 14, 2019·Frontiers in Pharmacology·Yue PanGary Guishan Xiao
Jan 13, 2015·Archives of Pharmacal Research·Sang-Min Jeon, Nissim Hay
Jul 22, 2019·Archives of Toxicology·Sabrina HeinzHeidrun Ellinger-Ziegelbauer
May 10, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Rattanaporn JaideeVeerapol Kukongviriyapan
Oct 9, 2012·Cancer Research·Shiva JaveshghaniMichael N Pollak
Apr 1, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alastair M Thompson

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft
light microscopy

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Zhonghua zhong liu za zhi [Chinese journal of oncology]
Hong-Meng ZhaoXu-Chen Cao
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
S M HadadA M Thompson
© 2022 Meta ULC. All rights reserved